Finally, we identified a novel master regulator, TRAFD1, influencing a set of genes enriched for two major pathways of immune activation, IFNγ signaling and antigen processing, which could thus be a potential target for therapeutic interventions in CeD. Here, TRAFD1 is linked to cranioectodermal dysplasia.